Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VER-155008 is a potent small molecule inhibitor of the heat shock protein 70 (Hsp70) family of molecular chaperones. It is an adenosine-derived compound that binds to the ATPase pocket of Hsp70 and inhibits its intrinsic ATPase activity. VER-155008 exhibits high affinity for Hsp70 (IC50 = 0.5 μM), as well as inhibitory activity against heat shock cognate 71 kDa protein (Hsc70) and glucose-regulated protein 78 kDa (Grp78), though with lower potency for these targets[1][2][3]. The inhibition of Hsp70 disrupts its anti-apoptotic functions in cancer cells and leads to reduced cell proliferation and increased apoptosis in various tumor cell lines including colon, breast cancer[1], and non-small-cell lung cancer[4]. In preclinical studies, it has also shown potential neuroprotective effects by reducing memory deficits and axonal degeneration in mouse models of Alzheimer's disease[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VER-155008.